Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts

D. German | R. Barker | R. Sperling | B. Dickerson | D. Blacker | J. Growdon | B. Hyman | A. Flaherty | A. Bonnet | M. Vidailhet | R. Albin | T. Hedden | S. Klebe | O. Rascol | B. Boot | D. Selkoe | A. Hartmann | C. Tanner | A. Lang | M. Frosch | D. Grabli | C. Brayne | J. Gusella | J. Marinus | T. Foltynie | S. McGinnis | I. Shoulson | S. Greenberg | F. Durif | B. Ravina | T. Gómez-Isla | J. Locascio | I. Jansen | P. Heutink | V. Mesnage | S. Forlani | A. Brice | S. Lesage | J. Corvol | S. Gomperts | C. Bonnet | V. Petyuk | F. Ory-Magne | A. Elbaz | E. Hedley‐Whyte | L. Sudarsky | R. Saunders-Pullman | Ganqiang Liu | J. Evans | C. Williams-Gray | S. Winder-Rhodes | A. Viswanathan | V. Khurana | A. Ascherio | M. Albers | G. Marshall | A. Hung | C. Brefel‐Courbon | D. Breen | A. Chen-Plotkin | O. Okereke | L. Lacomblez | P. Derkinderen | M. Schwarzschild | F. Bourdain | S. Eberly | C. Scherzer | A. Ivinson | G. Cummins | K. Tahiri | J. J. Hilten | Zhixiang Liao | M. Schlossmacher | J. Brandel | A. Mallet | N. Sharma | G. Mangone | F. Cormier‐Dequaire | R. Dewey | R. Alcalay | Haining Li | N. Mejia | Chizoba C. Umeh | Dubois Bowman | Jessica E Kloppenburg | T. Robbins | R. Barker | U. S. Sohur | K. Page | A. West | A. Wills | A. Trisini-Lipsanopoulos | M. Hayes | Daly Franco | M. Alora-Palli | T. Yi | A. Koenig | F. Ory‐Magne | G. Stålberg | J. V. van Hilten | Kyle Burke | Marta Marquis-Sayagues | Anat Stemmer-Rachaminov | S. Mason | Fernando Picó | Ted Dawson | David Vaillancourt | Jing Zhang | C. Williams‐Gray | R. Barker

[1]  Marios Politis,et al.  Cognitive decline in Parkinson disease , 2017, Nature Reviews Neurology.

[2]  M. Albert,et al.  Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. , 2016, JAMA neurology.

[3]  R. Barker,et al.  Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's , 2016, Annals of neurology.

[4]  C. Mariani,et al.  Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters , 2016, Annals of neurology.

[5]  D. Vaillancourt,et al.  The NINDS Parkinson's disease biomarkers program , 2016, Movement disorders : official journal of the Movement Disorder Society.

[6]  Tomoko Oeda,et al.  Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease , 2015, Neurobiology of Aging.

[7]  J. Trojanowski,et al.  Longitudinal study of normal cognition in Parkinson disease , 2015, Neurology.

[8]  J. Growdon,et al.  Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. , 2015, Brain : a journal of neurology.

[9]  Nicholas Eriksson,et al.  NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases , 2015, Neurobiology of Aging.

[10]  J. Trojanowski,et al.  Conversion between Mini‐Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale‐2 scores in Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[11]  T. Montine,et al.  APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. , 2014, JAMA neurology.

[12]  J. Marinus,et al.  Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG. , 2014, Parkinsonism & related disorders.

[13]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[14]  Henrik Zetterberg,et al.  CSF Aβ42 predicts early-onset dementia in Parkinson disease , 2014, Neurology.

[15]  R. Mehanna.  Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study , 2014, Neurology.

[16]  R. Barker,et al.  Sleep and circadian rhythm regulation in early Parkinson disease. , 2014, JAMA neurology.

[17]  P. Calabresi,et al.  Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease , 2014, Front. Aging Neurosci..

[18]  Jean-François Dartigues,et al.  Estimating and comparing time‐dependent areas under receiver operating characteristic curves for censored event times with competing risks , 2013, Statistics in medicine.

[19]  J. Roberts,et al.  Genetic susceptibility testing for neurodegenerative diseases: Ethical and practice issues , 2013, Progress in Neurobiology.

[20]  M. Zimmerman,et al.  Severity classification on the Hamilton Depression Rating Scale. , 2013, Journal of affective disorders.

[21]  T. Robbins,et al.  The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  R. Barker,et al.  Determinants of delayed diagnosis in Parkinson’s disease , 2013, Journal of Neurology.

[23]  M. Ban,et al.  Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. , 2013, Brain : a journal of neurology.

[24]  Keith A. Johnson,et al.  Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia , 2013, Neurology.

[25]  T. Beccari,et al.  First pilot newborn screening for four lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[26]  G. Stebbins,et al.  Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society‐unified Parkinson's disease rating scale scores , 2012, Movement disorders : official journal of the Movement Disorder Society.

[27]  Eden R Martin,et al.  Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2 , 2012, Annals of neurology.

[28]  G. Grabowski,et al.  Is E326K glucocerebrosidase a polymorphic or pathological variant? , 2012, Molecular genetics and metabolism.

[29]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[30]  J. Growdon,et al.  Association of SNCA with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker Study , 2011, Movement disorders : official journal of the Movement Disorder Society.

[31]  J. Marinus,et al.  SPES/SCOPA and MDS-UPDRS: formulas for converting scores of two motor scales in Parkinson's disease. , 2011, Parkinsonism & related disorders.

[32]  M. Horowitz,et al.  The enigma of the E326K mutation in acid β-glucocerebrosidase. , 2011, Molecular genetics and metabolism.

[33]  C. Adler,et al.  MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI , 2011, Movement disorders : official journal of the Movement Disorder Society.

[34]  J. Marinus,et al.  SCOPA‐cognition cutoff value for detection of Parkinson's disease dementia , 2011, Movement disorders : official journal of the Movement Disorder Society.

[35]  Dagmar Verbaan,et al.  The MoCA: Well-suited screen for cognitive impairment in Parkinson disease , 2011, Neurology.

[36]  J. Trojanowski,et al.  CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease , 2010, Neurology.

[37]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[38]  A. Siderowf,et al.  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease , 2009, Neurology.

[39]  S. Anderson,et al.  Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort , 2009, Neurology.

[40]  Thomas Foltynie,et al.  The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. , 2009, Brain : a journal of neurology.

[41]  C. Tanner,et al.  A longitudinal program for biomarker development in Parkinson's disease: A feasibility study , 2009, Movement disorders : official journal of the Movement Disorder Society.

[42]  C. Scherzer.  Chipping away at diagnostics for neurodegenerative diseases , 2009, Neurobiology of Disease.

[43]  D. Aarsland,et al.  Cognitive impairment in incident, untreated Parkinson disease , 2009, Neurology.

[44]  D. Aarsland,et al.  APOE Alleles in Parkinson Disease and Their Relationship to Cognitive Decline: A Population-based, Longitudinal Study , 2009, Journal of geriatric psychiatry and neurology.

[45]  T. Foroud,et al.  Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset , 2009, Neurology.

[46]  G. Halliday,et al.  The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years , 2008, Movement disorders : official journal of the Movement Disorder Society.

[47]  E. Tolosa,et al.  Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force , 2007, Movement disorders : official journal of the Movement Disorder Society.

[48]  E. Tolosa,et al.  Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[49]  A M Stiggelbout,et al.  Patient-reported autonomic symptoms in Parkinson disease , 2007, Neurology.

[50]  T. Robbins,et al.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. , 2007, Brain : a journal of neurology.

[51]  Tania B. Huedo-Medina,et al.  Assessing heterogeneity in meta-analysis: Q statistic or I2 index? , 2006, Psychological methods.

[52]  D. Aarsland,et al.  A systematic review of prevalence studies of dementia in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[53]  P. Heagerty,et al.  Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.

[54]  W. Poewe,et al.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[55]  T. Robbins,et al.  The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. , 2004, Brain : a journal of neurology.

[56]  A M Stiggelbout,et al.  A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[57]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[58]  D. Aarsland,et al.  Risk of dementia in Parkinson’s disease: A community-based, prospective study , 2001 .

[59]  Marjan Jahanshahi,et al.  What contributes to quality of life in patients with Parkinson's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[60]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[61]  K. Marder,et al.  The frequency and associated risk factors for dementia in patients with Parkinson's disease. , 1995, Archives of neurology.

[62]  K. Marder,et al.  A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. , 1992, Archives of neurology.

[63]  J. Jankovic,et al.  Variable expression of Parkinson's disease , 1990, Neurology.

[64]  M. Pollock,et al.  The prevalence, natural history and dementia of Parkinson's disease. , 1966, Brain : a journal of neurology.

[65]  J. Sinsheimer,et al.  APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression. , 2016, Journal of Parkinson's disease.

[66]  E. O. Perez,et al.  Ethics Research Compendium , 2013 .

[67]  M. Vidailhet,et al.  Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. , 2011, Human molecular genetics.

[68]  E. Beutler,et al.  Hematologically important mutations: Gaucher disease. , 2005, Blood cells, molecules & diseases.

[69]  Jack L. Vevea,et al.  Fixed- and random-effects models in meta-analysis. , 1998 .

[70]  P. Grambsch,et al.  A Package for Survival Analysis in S , 1994 .

[71]  DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. , 1989, Archives of neurology.